Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease

HSS Journal

Volumn 5, Issue 2, 2009, Pages 169-177

  Gordon, Jessica K ^a   Magro, Cynthia ^b   Lu, Theresa ^a   Schneider, Robert ^a   Chiu, April ^b   Furman, Richard R ^b   Solomon, Garron ^b   Bass, Anne ^a   Erkan, Doruk ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350675953     PISSN: 15563316     EISSN: 15563324     Source Type: Journal    
DOI: 10.1007/s11420-009-9123-x     Document Type: Article

References (32)

1. Jang YJ, Park KH Seok HJ (2000) Management of Kikuchi's disease using glucocorticoid. J. Laryngol. Otol. 114:709-11.
2. Rezai K, Kuchipudi S, Chundi V (2004) Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment. Clin. Infect. Dis 39:e124-e126.
3. Lawrence RC, Helmick CG, Arnett FC (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41:778-799.
4. Jimenez S, Cervera R, Font J (2003) The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 25:3-12.
5. El-Ramahi KM, Karrar A, Ali MA (1994) Kikuchi disease and its association with systemic lupus erythematosus. Lupus 3:409-11.
6. Goldblatt F, Andrews J, Russell A, Isenberg D (2008) Association of Kikuchi-Fujimoto's disease with SLE. Rheumatology 47:554-555.
7. Eisner MD, Amory J, Mullaney B (1996) Necrotizing lymphadenitis associated with systemic lupus erythematosus. Semin. Arthritis Rheum. 26:1-6.
8. Ohshima K, Karube K, Hamasaki M (2004) Apoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotising lymphadenitis. Eur. J. Haematol. 72:322-9.
9. Kato K, Ohshima K, Anzai K (2001) Elevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitis. Int. J. Hematol. 73:84-6.
10. Kozyrev SV, Lewén S, Reddy PM (2007) Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 56:1234-41.
11. Niewold TB, Kelly JA, Flesch MH (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481-7.
12. Graham RR, Kyogoku C, Sigurdsson S, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 104:6758-6763.
13. Kirou KA, Mavragani CP, Crow MK (2007) Activation of typeI interferon in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 3:579-588.
14. Barrat FJ, Meeker T, Gregorio J, et al. (2005) Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131-1139.
15. Cella M, Jarrossay D, Facchetti F (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919-923.
16. Qu C, Moran TM, Randolph GJ (2003) Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J. Immunol 170:1010-1018.
17. Tsang WY, Chan JK, Ng CS (1994) Kikuchi's lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am. J. Surg. Pathol. 18:219-231.
18. Heremans H, Billiau A, Colombatti A (1978) Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun. 21:925-930.
19. Braun D, Geraldes P, Demengeot J (2003) Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20:15-25.
20. Adam C, Thoua Y, Ronco P (1980) The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin. Exp. Immunol. 40:373-382.
21. Mathian A, Weinberg A, Gallegos M (2005) IFN-{alpha} induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but Not in BALB/c Mice. J. Immunol. 174:2499-2506.
22. Santiago-Raber ML, Baccala R, Haraldsson KM (2003) Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice. J. Exp. Med. 197:777-788.
23. Hron JD, Peng SL (2004) Type I IFN protects against murine lupus. J. Immunol. 173:2134-2142.
24. Baechler EC, Batliwalla FM, Karypis G (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610-2615.
25. Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481-490.
26. Bennett L, Palucka AK, Arce E (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723.
27. Kirou KA, Lee C, George S (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958-3967.
28. Farkas L, Beiske K, Lund-Johansen F (2001) Plasmacytoid dendritic cells (natural interferon- {{alpha}}/{beta}-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237-243.
29. Blomberg S, Eloranta ML, Cederblad B (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10:484-490.
30. Nakano H, Yanagita M, Gunn MD (2001) CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171-1178.
31. Yoneyama H, Matsuno K, Toda E (2005) Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J. Exp. Med. 202:425-435.
32. Shiow LR, Rosen DB, Brdickova N, et al., CD69 acts downstream of interferon-[alpha]/[beta] to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540-544.